208 related articles for article (PubMed ID: 17591831)
1. The role of Aurora-A inhibitors in cancer therapy.
Agnese V; Bazan V; Fiorentino FP; Fanale D; Badalamenti G; Colucci G; Adamo V; Santini D; Russo A
Ann Oncol; 2007 Jun; 18 Suppl 6():vi47-52. PubMed ID: 17591831
[TBL] [Abstract][Full Text] [Related]
2. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
3. Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.
Pérez Fidalgo JA; Roda D; Roselló S; Rodríguez-Braun E; Cervantes A
Clin Transl Oncol; 2009 Dec; 11(12):787-98. PubMed ID: 20045785
[TBL] [Abstract][Full Text] [Related]
4. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
5. Aurora-B kinase inhibitors for cancer chemotherapy.
Yeung SC; Gully C; Lee MH
Mini Rev Med Chem; 2008 Dec; 8(14):1514-25. PubMed ID: 19075809
[TBL] [Abstract][Full Text] [Related]
6. Targeting aurora kinases in cancer treatment.
Kelly KR; Ecsedy J; Mahalingam D; Nawrocki ST; Padmanabhan S; Giles FJ; Carew JS
Curr Drug Targets; 2011 Dec; 12(14):2067-78. PubMed ID: 21777198
[TBL] [Abstract][Full Text] [Related]
7. Aurora kinase inhibitors as anticancer molecules.
Katayama H; Sen S
Biochim Biophys Acta; 2010; 1799(10-12):829-39. PubMed ID: 20863917
[TBL] [Abstract][Full Text] [Related]
8. Aurora A and B kinases--targets of novel anticancer drugs.
Libertini S; Abagnale A; Passaro C; Botta G; Portella G
Recent Pat Anticancer Drug Discov; 2010 Nov; 5(3):219-41. PubMed ID: 20524930
[TBL] [Abstract][Full Text] [Related]
9. VX-680 inhibits Aurora A and Aurora B kinase activity in human cells.
Tyler RK; Shpiro N; Marquez R; Eyers PA
Cell Cycle; 2007 Nov; 6(22):2846-54. PubMed ID: 18032922
[TBL] [Abstract][Full Text] [Related]
10. Aurora kinase inhibitors: progress towards the clinic.
Kollareddy M; Zheleva D; Dzubak P; Brahmkshatriya PS; Lepsik M; Hajduch M
Invest New Drugs; 2012 Dec; 30(6):2411-32. PubMed ID: 22350019
[TBL] [Abstract][Full Text] [Related]
11. Aurora B: a new prognostic marker and therapeutic target in cancer.
Portella G; Passaro C; Chieffi P
Curr Med Chem; 2011; 18(4):482-96. PubMed ID: 21143115
[TBL] [Abstract][Full Text] [Related]
12. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
Warner SL; Gray PJ; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
[TBL] [Abstract][Full Text] [Related]
13. Aurora-A kinase regulates NF-kappaB activity: lessons from combination studies.
Linardopoulos S
J BUON; 2007 Sep; 12 Suppl 1():S67-70. PubMed ID: 17935280
[TBL] [Abstract][Full Text] [Related]
14. Target validation and biomarker identification in oncology : the example of aurora kinases.
Colombo R; Moll J
Mol Diagn Ther; 2008; 12(2):71-6. PubMed ID: 18422371
[TBL] [Abstract][Full Text] [Related]
15. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
16. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
17. Validating Aurora B as an anti-cancer drug target.
Girdler F; Gascoigne KE; Eyers PA; Hartmuth S; Crafter C; Foote KM; Keen NJ; Taylor SS
J Cell Sci; 2006 Sep; 119(Pt 17):3664-75. PubMed ID: 16912073
[TBL] [Abstract][Full Text] [Related]
18. Targeting Aurora-2 kinase in cancer.
Warner SL; Bearss DJ; Han H; Von Hoff DD
Mol Cancer Ther; 2003 Jun; 2(6):589-95. PubMed ID: 12813139
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of Aurora kinase inhibitors in cancer.
Naruganahalli KS; Lakshmanan M; Dastidar SG; Ray A
Curr Opin Investig Drugs; 2006 Dec; 7(12):1044-51. PubMed ID: 17209521
[TBL] [Abstract][Full Text] [Related]
20. Emerging cancer therapeutic opportunities by inhibiting mitotic kinases.
Pérez de Castro I; de Cárcer G; Montoya G; Malumbres M
Curr Opin Pharmacol; 2008 Aug; 8(4):375-83. PubMed ID: 18644252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
